- Recognition Marks Alnylam’s Seventh Year in a Row on this Prestigious List, and its First Time Ranking #1 -
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has ranked first in Boston Globe’s 2021 Top Places to Work in the “Largest Employer” category. This is the seventh consecutive year that Alnylam has been named a Top Place to Work by the Boston Globe and the first year that Alnylam has been eligible for the Largest Employer category (> 1,000 employees).
Companies named to the Top Places to Work list are chosen by the people who best understand the workplace environment, the employees. Employees complete an anonymous, research-backed survey assessing categories such as their company’s direction, execution, connection, management, work, pay and benefits. The list spotlights companies that support employees both in and out of the office, including caregiving, mental health, and other out-of-office needs. This recognition comes on the heels of Alnylam’s recent inclusion on Science Magazine’s Top Employer list for the third consecutive year.
“At Alnylam, we are changing the way disease is treated through the pursuit of innovative science, and that is only possible with a remarkable team,” said John Maraganore, Ph.D., Founding Chief Executive Officer of Alnylam. “Despite the ongoing challenges of 2021, our colleagues banded together to find creative ways to continue to innovate, collaborate, and deliver on behalf of the patients that depend on us. Our run of seven years in a row is a testament to that while our pioneering science is our foundation, our people are truly what makes Alnylam amazing.”
The Top Places to Work survey is completed by 80,000 employees, across 363 different companies in Massachusetts. The winners share key traits including more flexibility to work remotely and a focus on DE&I initiatives. For a full list of winners, please visit https://www.bostonglobe.com/magazine/top-places-work/2021.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO® (lumasiran), as well as Leqvio® (inclisiran), which is being developed and commercialized by Alnylam’s partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)